WeVote
Log In

Bill

Bill

A 5187

Requires NJT to establish pilot program to supply certain light rail train sets with opioid antidotes; makes appropriation of $100,000.

2024-2025 Regular Session Introduced by Anthony Verrelli

New Jersey requires NJT to pilot naloxone distribution on light rail trains with $100,000 in funding to address overdose emergencies in transit.

Introduced in the Assembly, Referred to Assembly Transportation and Independent Authorities Committee
#freightrail
0
WeVote Research Nonpartisan
Bill Summary · A 5187

Legislative bill overview

Bill A 5187 requires New Jersey Transit (NJT) to establish a pilot program that equips certain light rail train sets with opioid antidotes (naloxone/Narcan). The bill appropriates $100,000 to fund this initiative and was introduced in the New Jersey Assembly in January 2025.

Why is this important

The opioid crisis continues to claim lives in public spaces, including transit systems where overdoses can be fatal if emergency medical help is delayed. Placing naloxone on trains could enable rapid intervention by NJT staff or passengers during overdose emergencies, potentially saving lives before paramedics arrive. This represents a preventive public health approach to addressing overdose deaths in high-traffic public facilities.

Potential points of contention

  • Cost-effectiveness and scope: $100,000 may be insufficient for comprehensive implementation across NJT's light rail system; unclear whether funds cover training, equipment maintenance, and staff education
  • Liability and responsibility: Questions about whether transit workers should be required to administer medical interventions, potential liability issues, and whether this diverts responsibility from healthcare providers
  • Pilot program design: The bill lacks specifics on which train sets participate, success metrics, evaluation timeline, or how results will inform broader policy decisions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.